Fei-Li Zhao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/133824/publications.pdf

Version: 2024-02-01

		933447	839539	
18	363	10	18	
papers	citations	h-index	g-index	
18	18	18	633	
	10	10	033	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients. Health and Quality of Life Outcomes, 2014, 12, 156.	2.4	57
2	Willingness to Pay per Quality-Adjusted Life Year: Is One Threshold Enough for Decision-Making?. Medical Care, 2011, 49, 267-272.	2.4	51
3	Statin is a Reasonable Treatment Option for Patients with Polycystic Ovary Syndrome: a Meta-analysis of Randomized Controlled Trials. Experimental and Clinical Endocrinology and Diabetes, 2012, 120, 367-375.	1.2	48
4	Validation and Comparison of EuroQol and Short Form 6D in Chronic Prostatitis Patients. Value in Health, 2010, 13, 649-656.	0.3	47
5	Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: A meta-analysis of randomized placebo-controlled trials. Epilepsy Research, 2013, 103, 31-44.	1.6	31
6	COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA. International Journal of Technology Assessment in Health Care, 2012, 28, 436-444.	0.5	24
7	Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis. Pharmacoeconomics, 2013, 31, 501-508.	3.3	24
8	Health-related quality of life in Chinese patients with chronic prostatitis/chronic pelvic pain syndrome. Quality of Life Research, 2010, 19, 1273-1283.	3.1	15
9	Potentiation of Adenosine A1 Receptor Agonist CPA-Induced Antinociception by Paeoniflorin in Mice. Biological and Pharmaceutical Bulletin, 2006, 29, 1630-1633.	1.4	13
10	Clinical pathways for primary care: effects on professional practice, patient outcomes, and costs. The Cochrane Library, 2013, , .	2.8	13
11	Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples. PLoS ONE, 2016, 11, e0147169.	2.5	10
12	Prevention of postpartum haemorrhage: cost consequences analysis of misoprostol in low-resource settings. BMC Pregnancy and Childbirth, 2015, 15, 305.	2.4	8
13	Monocyte-Mediated Rotenone Neurotoxicity towards Human Neuroblastoma SH-SY5Y: Role of Mitogen-Activated Protein Kinases. Biological and Pharmaceutical Bulletin, 2006, 29, 1372-1377.	1.4	6
14	Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy?. Value in Health Regional Issues, 2013, 2, 152-159.	1.2	4
15	Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis of Randomized Controlled Trials. Value in Health Regional Issues, 2015, 6, 22-32.	1.2	4
16	Down regulation of cyclooxygenase-2 is involved in delayed neuro-protection by ischemic preconditioning in rats. Acta Pharmacologica Sinica, 2005, 26, 441-446.	6.1	3
17	Discrepancies between proxy estimates and patient reported, health related, quality of life: minding the gap between patient and clinician perceptions in heart failure. Quality of Life Research, 2021, 30, 1049-1059.	3.1	3
18	Psychometric Evaluation of the Mandarin HeartQoL Health-Related Quality of Life Questionnaire Among Patients With Ischemic Heart Disease in China. Value in Health Regional Issues, 2022, 31, 53-60.	1.2	2